S
Steven Tran
Researcher at St. Vincent's Health System
Publications - 14
Citations - 113
Steven Tran is an academic researcher from St. Vincent's Health System. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 4, co-authored 9 publications receiving 74 citations.
Papers
More filters
Journal ArticleDOI
Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).
John A. Snowden,Riccardo Saccardi,Kim Orchard,Per Ljungman,Rafael F. Duarte,Myriam Labopin,Eoin McGrath,Nigel Brook,Carmen Ruiz de Elvira,Debra Gordon,Hélène Poirel,Francis Ayuk,Yves Beguin,Francesca Bonifazi,Alois Gratwohl,Noel Milpied,John Moore,Jakob Passweg,J. Douglas Rizzo,Stephen R. Spellman,Jorge Sierra,Carlos Solano,Fermín Sánchez-Guijo,Nina Worel,Andreu Gusi,Gillian Adams,Theodor A. Balan,Helen Baldomero,Gilles Macq,Evelyne Marry,Florence Mesnil,Elena Oldani,Rachel Pearce,Julia Perry,Nicole Raus,Urs Schanz,Steven Tran,Leonie Wilcox,Grzegorz W. Basak,Christian Chabannon,Selim Corbacioglu,Harry Dolstra,Jürgen Kuball,Mohamad Mohty,Arjan C. Lankester,Sylvia Montoto,Arnon Nagler,Jan Styczyński,Ibrahim Yakoub-Agha,Régis Peffault de Latour,Nicolaus Kroeger,Ronald Brand,Liesbeth C. de Wreede,Erik W. van Zwet,Hein Putter +54 more
TL;DR: In this article, the authors developed a risk-adapted international benchmarking model for one-year survival following allogeneic and autologous HSCT based on current capabilities within the EBMT registry core dataset.
Journal ArticleDOI
Second Cancer Risk and Late Mortality in Adult Australians Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Population-Based Cohort Study.
Claire M. Vajdic,Eleni Mayson,Anthony J. Dodds,Tracey A. O'Brien,Leonie Wilcox,Ian Nivison-Smith,Renate E. Le Marsney,Benjamin Daniels,Lesley J. Ashton,L. Ashton,R.E. Le Marsney,A. Dodds,Joanne L. C. Tan,Ian Bilmon,L. Wilcox,I. Nivison-Smith,Donna Aarons,Steven Tran,C. Vajdic,Jerry D. Gibson,Anne Maree Johnston,M. Greenwood,M. Forbes,Mark Hertzberg,Gillian Huang,Andrew Spencer,Jenny Muirhead,Jeff Szer,Kylie D. Mason,Ian D. Lewis,C. To,Simon Durrant,R Western,Paul Cannell,S. Buffery,T. O'Brien,Cecilia Oswald,Adam S. Nelson,Peter J. Shaw,L. Pearson,Karin Tiedemann,M. Scoyne,Chris Fraser,J. Seljak,Catherine H. Cole,K. Rowland,H. Gough,Heather Tapp,Nicola H. Green +48 more
TL;DR: Cancer risk relative to the general population was elevated for those transplanted for lymphoma, some leukemia subtypes, and severe aplastic anemia, recipients who developed chronic graft-versus-host disease (cGVHD) and irrespective of radiation-based conditioning or stem cell source.
Journal ArticleDOI
A Review of Hematopoietic Cell Transplantation in Australia and New Zealand, 2005 to 2013.
Ian Nivison-Smith,Peter Bardy,Anthony J. Dodds,David D.F. Ma,Donna Aarons,Steven Tran,Leonie Wilcox,Jeff Szer +7 more
TL;DR: Overall survival probabilities at 5 years after transplantation for adult (16+) allogeneic first HCT recipients were 54.2% for ALL, 46.0% for AML, 48.4% for myelodysplastic syndromes, and 58.6% for NHL.
Journal ArticleDOI
Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG.
Jad Othman,Matthew Greenwood,Matthew Greenwood,John Moore,John Moore,Stephen Larsen,Stephen Larsen,Anne-Marie Watson,Christopher Arthur,Abir Bhattacharyya,Ian Bilmon,Emily Blyth,Adam Bryant,Christian E Bryant,Lindsay Dunlop,Keith Fay,Keith Fay,John Gibson,John Gibson,Nada Hamad,Nada Hamad,Ian Kerridge,Ian Kerridge,John Kwan,David D.F. Ma,David D.F. Ma,Kenneth P. Micklethwaite,Sam Milliken,Sam Milliken,Shyam Panicker,William Stevenson,William Stevenson,Barbara Withers,Barbara Withers,Leonie Wilcox,Steven Tran,David Gottlieb,David Gottlieb +37 more
TL;DR: Results of HSCT performed using an URD with ATG during conditioning were superior to transplant from a MRD without ATG, and the addition of Thymoglobuline to conditioning in HSCT from MRD should be further examined in prospective trials.
Journal ArticleDOI
Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry.
Yadanar Lwin,Glenn Kennedy,Glenn Kennedy,David Gottlieb,David Gottlieb,John Kwan,John Kwan,David Ritchie,David Ritchie,David Ritchie,Jeff Szer,Jeff Szer,Jeff Szer,Sam Milliken,Peter Browett,Andrew Spencer,Andrew Butler,Peter G Bardy,Matthew Greenwood,Matthew Greenwood,Travis Perera,Simon He,Ashley McEwan,Stephen Larsen,Hock Choong Lai,Duncan Purtill,Steven Tran,Donna Aarons,Nada Hamad,Nada Hamad +29 more
TL;DR: There have been no improvements in MF allo-SCT outcomes in Australasia in the last decades with low uptake of molecular genomic technology due to limited funded access.